# Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

> **NCT01245205** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Akt inhibitor MK2206
- **DRUG:** lapatinib ditosylate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01245205
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-08
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245205, "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01245205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*